

PATENT

ATTORNEY DOCKET NO. 07257/017004

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Michael Karin et al.

Art Unit: 1814

Serial No.: 08/799,913

Examiner: C. Patterson

Filed: 02/13/97

Title : ONCOPROTEIN PROTEIN KINASE

Assistant Commissioner for Patents  
Washington, DC 20231PERMISSION TO USE SEQUENCE LISTING

The above-identified patent application lacks a substitute paper copy of the Sequence Listing for inclusion into the Specification, as well as a computer readable form of the Sequence Listing. Applicants respectfully direct the attention of the Office to the following:

1. A complete paper copy of the Sequence Listing is to be inserted in the Specification at pages ~~62~~ 72-73. This paper copy is identical to the paper copy of the Sequence Listing which is included in the Specification of the parent priority patent; to wit, U.S. Patent Application Serial No. 08/444,393, which is now issued U.S. Patent No. 5,605,808 (the "393 application").

Date of Deposit September 17, 1997  
I hereby certify that this correspondence is being facsimile transmitted  
to the Patent and Trademark Office on the date indicated above.

Lucille M. Begalla  
Lucille M. Begalla

2. A computer-readable form of the Sequence Listing identical to the paper copy of the Sequence Listing is on file in the '393 application. Pursuant to 37 CFR §1.821(e) I, reference to the computer-readable form on file in the '393 application is hereby made, which computer-readable form was filed in the '393 application on January 22, 1996. Said computer-readable form is identical to both the paper copy of the Sequence Listing on file in the '393 application and the paper copy of the Sequence Listing submitted in the present application.

Applicants submit that the foregoing satisfies the requirements of Rule 1.821. If there are any questions regarding this response, the Office is invited to contact the undersigned.

It is understood that this perfects the application and no additional papers or filing fees are required. If there are any other charges, or any credits, please apply them to Deposit Account No. 06-1050.

Respectfully submitted,

Date: 9/17/97



Lisa A. Haile, Ph.D.  
Reg. No. 38,347

Fish & Richardson P.C.  
4225 Executive Square, Suite 1400  
La Jolla, CA 92037

Telephone: 619/678-5070  
Facsimile: 619/678-5099

41245

## ALLOWED CLAIMS

U.S. Patent Application Serial No. 08/711,893

Entitled: ONCOPROTEIN PROTEIN KINASE

Inventors: Karin et al.

Filed: 09/12/96

Docket No.: 07257/017003

24. A method of treating a cell proliferative disorder associated with c-Jun N-terminal kinase having a molecular weight of 46 kD or 55 kD as determined by reducing SDS-PAGE; having serine and threonine kinase activity; and phosphorylating the c-Jun N-terminal activation domain, comprising administering to a subject with the disorder, a therapeutically effective amount of reagent which modulates the kinase activity.
25. The method of claim 24, wherein the reagent is an antisense polynucleotide sequence.
26. The method of claim 24, wherein the reagent is an antibody.